Sorted By Test Name - Mayo Medical Laboratories

F_10
9066
VIII are the most commonly occurring specific inhibitors of coagulation factors and can produce serious
bleeding disorders (acquired hemophilia). Factor VIII is highly susceptible to proteolytic inactivation,
with the potential for spuriously decreased assay results.
Useful For: Diagnosing hemophilia A Diagnosing von Willebrand disease when measured with the
von Willebrand factor (VWF) antigen and VWF activity Diagnosing acquired deficiency states
Investigation of prolonged activated partial thromboplastin time
Interpretation: See Cautions. Mild hemophilia A: 5% to 50% Moderate hemophilia A: 1% to 5%
Severe hemophilia A: or =180 days postnatal.*
*See Pediatric Hemostasis References in Coagulation Studies in Special Instructions.
Clinical References: 1. Girolami A, Scandellari R, Scapin M, Vettore S: Congenital bleeding
disorders of the vitamin K-dependent clotting factors. Vitam Horm 2008;78:281-374 2. Brenner B,
Kuperman AA, Watzka M, Oldenburg J: Vitamin K-dependent coagulation factors deficiency. Semin
Thromb Hemost 2009 Jun;35(4):439-446 3. Menegatti M, Peyvandi F: Factor X deficiency. Semin
Thromb Hemost 2009 Jun;35(4):407-415 4. Girolami A, Ruzzon E, Tezza F, et al: Congenital FX
deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the
literature. Haemophilia 2008;14(2):323-328 5. Girolami A, Scarparo P, Scandellari R, Allemand E:
Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic
system: a critical evaluation. Am J Hematol 2008;83(8):668-671
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 489